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In humans, thiamine is a micronutrient prone to depletion that may result in severe 
clinical abnormalities. This narrative review summarizes current knowledge on thiamine 
deficiency (TD) and bridges the gap between pathophysiology and clinical presentation 
by integrating thiamine metabolism at subcellular level with its function to vital organs. 
The broad clinical spectrum of TD is outlined, with emphasis on conditions encountered 
in tropical pediatric practice. In particular, TD is associated with type B lactic acidosis 
and classic forms of beriberi in children, but it is often unrecognized. Other severe acute 
conditions are associated with hypermetabolism, inducing a functional TD. The crucial 
role of thiamine in infant cognitive development is also highlighted in this review, along 
with analysis of the potential impact of TD in refeeding syndrome during severe acute 
malnutrition (SAM). This review aims to increase clinical awareness of TD in tropical 
settings where access to diagnostic tests is poor, and advocates for an early therapeu-
tic thiamine challenge in resource-limited settings. Moreover, it provides evidence for 
thiamine as treatment in critical conditions requiring metabolic resuscitation, and gives 
rationale to the consideration of increased thiamine supplementation in therapeutic 
foods for malnourished children.
Keywords: thiamine, thiamine deficiency, tropical pediatrics, beriberi, refeeding syndrome, pediatric critical care, 
type B lactic acidosis, thiamine transporters 
iNTRODUCTiON
Thiamine (Vitamin B1) is an essential micronutrient with dual coenzymatic and non-coenzymatic 
functions. It is involved in carbohydrate and branched-chain amino acid metabolism, as well as in 
the production of neurotransmitters, myelin, and nucleic acids. There is also evidence that thiamine 
plays a role in immune and anti-inflammatory processes and gene regulation (1–4).
Abbreviations: AThDP, adenosine thiamine diphosphate; AThTP, adenosine thiamine triphosphate; hTHTRs, human thiamine 
transporters; M-ThPP-T, mitochondrial thiamine pyrophosphate transporter; Spectrum MR, spectrum magnetic resonance; 
TD, thiamine deficiency; ThDP, thiamine diphosphate; ThTP, thiamine triphosphate; ThTr1, thiamine transporter 1; ThTr2, 
thiamine transporter 2; TPK, thiamine pyrophosphokinase.
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As an essential micronutrient, the body’s requirements are 
exclusively dependent on dietary supply as there is no endog-
enous synthesis. The combination of limited body storage and a 
high turnover rate (half-life <10 days) results in potential deple-
tion of thiamine stores within 2 weeks if it is not continuously 
replaced. In addition, thiamine’s hydrosolubility, coupled with its 
renal clearance profile, contributes to a propensity to thiamine 
deficiency (TD) throughout life.
In pediatrics, the overall clinical picture of TD is not easy to 
recognize, mimicking or being confused with other diseases. Not 
surprisingly, the likelihood of misdiagnosis of TD is even greater 
in resource-limited settings (5–7). Despite being easily treatable, 
TD continues to be seen in all age groups in both high and low 
resource countries with potentially severe and life-threatening 
consequences (8–12).
This article focuses initially on thiamine physiology from 
ingestion in the diet to uptake and metabolism at mitochon-
drion level and the circumstances leading to TD in tropical 
pediatrics. By highlighting the essential role of thiamine in 
various body functions, this article enables us to better under-
stand the spectrum of clinical presentations of TD in children, 
including the various manifestations of beriberi, refeeding 
syndrome in malnutrition, severe clinical states requiring 
resuscitation, and conditions linked to anti-thiamine factors. 
A brief overview of diagnosis and treatment of TD concludes 
the paper and gives suggestions for the way forward in the 
management of TD.
THiAMiNe MeTABOLiSM: A 
PHYSiOLOGiCAL SNAPSHOT OF 
THiAMiNe iN HUMANS
Ingested dietary thiamine is essential to meet body requirements 
in humans who are unable to synthesize it naturally. The daily 
requirement of thiamine depends on age, body weight, physi-
ological conditions, and individual metabolism with respect to 
the overall energy content in the diet.
Unlike for adults, recommendations of the optimal thiamine-
caloric ratio (mg/1000 kcal/day of energy consumed) are not yet 
firmly established in pediatrics (9, 13). In children, whose caloric 
needs are age dependent, the estimated daily recommended 
dietary allowance (RDA) is 0.2 mg up to 6 months of age, 0.3 mg 
from 7 months to 3 years of age, and 0.6 mg between 4 and 8 years 
of age. Over 8 years, daily RDA varies from 0.9 mg up to 1.2 mg.
The content of thiamine and its derivatives in breast milk 
is around 0.21  mg/l, but varies widely according to diet and 
countries. Nevertheless, thiamine-deficient breast milk is not 
uncommon and can have a serious effect on infant thiamine 
status during exclusive breastfeeding (14, 15).
Body Thiamine Distribution
After ingestion, free thiamine absorption occurs mainly in the 
proximal small intestine either via a saturable carrier-mediated 
system for low thiamine concentrations, or by passive diffusion 
for high concentrations. Inside the polarized enterocyte, the vec-
torial transport of thiamine is through specific human thiamine 
transporters-hTHTRs (ThTr1 and 2) (16–18), after which free 
thiamine disperses throughout the cell. Genetic defects in ThTr1 
(SLC19A2) and ThTr2 (SLC19A3) result in thiamine-responsive 
megaloblastic anemia (TRMA) and biotin-responsive basal 
ganglia disease (BBGD), respectively (2, 19, 20).
Intracellular-free thiamine is phosphorylated into thiamine 
monophosphate (ThMP), then thiamine diphosphate (ThDP) 
[also known as thiamine pyrophosphate (ThPP)], and finally 
thiamine triphosphate (ThTP). In the enterocyte, thiamine is 
phosphorylated to ThDP by thiamine pyrophosphokinase (TPK), 
before being transported from the cell apex toward the opposite 
pole. Most of this ThDP is then hydrolyzed to cross the basolateral 
membrane using an adenosine triphosphate (ATP)-dependent 
transporter. From here, thiamine gets into the portal blood to 
reach the liver and tissues via different pathways. Besides the 
classic hTHTRs, other carriers include alkaline/acid phosphatase 
transport and the organic cation transporter groups (OCT1), 
acting as hydrosoluble organic cations (1, 16–18, 21). Thiamine 
subsequently joins the systemic bloodstream either as a free 
form or incorporated in circulating cells, mainly erythrocytes 
(Figure 1A). It targets body cells that utilize glucose as their main 
fuel; however, thiamine tissue tropism depends on the degree of 
expression of key transporters on cell membranes in the major 
body systems (splanchnic, nervous, muscular and renal systems, 
and the placenta) (1, 2, 16–18, 21, 22).
In the splanchnic system, the liver and the pancreas are the two 
most important targets (21, 23). Recent evidence indicates that 
human colonic epithelial cells express specific ThDP transporters 
(SCL44A4) able to uptake thiamine, which is a local by-product 
of gut microbiota in infancy (Prevotella enterotype 2). It is not 
yet fully understood whether this microbiome-related thiamine 
pool is solely used in situ or contributes to whole body thiamine 
homeostasis (24, 25).
In the nervous system, central neurons  –  known for their 
high oxidative metabolism  –  astrocytes, and peripheral nerves 
are involved in the biosynthesis of a number of neurotransmit-
ters, including acetylcholine (26, 27). Evidence suggests that the 
brain appears to be the ultimate target of thiamine (1, 2, 28, 29). 
Thiamine crosses the blood–brain barrier via carrier proteins to 
reach select regions of the brain, but the exact pathophysiology of 
this tropism is poorly understood (30–32). There are key differ-
ences in the distribution of thiamine derivatives throughout the 
brain, providing some insight into thiamine’s apparent preference 
for certain neuronal tissues. The ThDP form is mainly present 
in neurons and is involved in cerebral oxidative metabolism. 
Conversely, the ThTP form, approximately 10% of the cerebral 
thiamine pool, is involved in membrane excitability and nerve 
conduction, acting as a modulator of the permeability of sodium 
chloride channels (29, 30, 33, 34). Similarly, the distribution of 
thiamine-related enzymes is compartmentalized, especially those 
with rate-limiting properties, which play a role in cerebral energy 
utilization. Therefore TD might cause brain tissue injury by 
inhibiting metabolism in cerebral regions with higher metabolic 
demands and high thiamine turnover (34–36). The magnitude of 
the rate of thiamine uptake by the blood–brain barrier highlights 
the huge cerebral demand for thiamine and the need for its con-
tinuous supply for brain activity (22, 30, 32). In vitro and in vivo 
A B C
FiGURe 1 | Simplified overview of thiamine intracellular action: focus on coenzymatic functions. (A) Infant thiamine distribution with its three main target 
organs; (B) thiamine cellular metabolism with its main pools and thiamine-related metabolic pathways; (C) zooming boxes: (C1) – cytosolic pentose phosphate 
pathways using transketolase, (C2) – HIF-1 alternative routes, (C3) – mitochondrial events; ThDP is a cofactor for PDH, α-KGDH and BCKD. Under hypoxia/
pseudo-hypoxia HIF1-α upregulates PDK1 that in turn downregulates PDH. Abbreviations: BCKD, branched-chain ketoacid dehydrogenase complex; LDH, lactic 
dehydrogenase leading to Type B acidosis; PDH, pyruvate dehydrogenase complex; PDK1, pyruvate dehydrogenase kinase; α-KGDH, alpha-ketoglutarate 
dehydrogenase. ATP, adenosine triphosphate; BCAA, branched-chain amino acids; Glut transporter, glucose transporter; HIF, hypoxia-inducible factor, as a dimeric 
(α, β unit) transcriptional factor; KC, Krebs cycle; M-TPP-T, mitochondrial thiamine pyrophosphate transporter; OAA, oxaloacetate; Succ-CoA, succinyl-coenzyme A; 
ThDP (or TPP), thiamine diphosphate; α-KG: α-ketoglutarate. (B) Intracellular dotted arrows: alternative pathways for pyruvate–lactate axis and for HIF-1 during 
Hypoxia/pseudo-hypoxia (e.g., TD).
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kinetics reinforce the idea that thiamine turnover is not homo-
geneous in the brain. It is higher in areas vulnerable to TD, and 
lower in other structures, such as the cerebral cortex (a relatively 
less sensitive region) (1, 30, 32, 34, 35). TD neurotropic effects are 
observed in various histological pathways of the brain, specifically 
causing disruption to the blood–brain barrier rich in endothelial 
mitochondria, choroid plexus dysfunction, differential damage in 
aerobic neurons and anaerobic astrocytes, microglial activation, 
perturbation in the glutamate system (with its specific transport-
ers), altered dynamics of intracellular calcium and endoplasmic 
reticulum stress (27, 29, 31, 37–41).
Smooth, skeletal and particularly cardiac myocytes, known 
for their high aerobic metabolism, are all affected by TD. Their 
dysfunction might result in the early manifestations of TD, 
such as gastrointestinal paresis and heart failure (6, 42, 43). 
In the kidneys, the determinants of thiamine renal clearance 
are glomerular filtration rate (GFR) and the saturable reab-
sorptive capacity of proximal tubules through the thiamine/
H+ antiport using hTHTRs, similar to polarized enterocytes 
(2, 18, 20, 44).
Lastly, during pregnancy, thiamine crosses the placental 
brush-border epithelium through a specific carrier (45, 46). This 
active transfer is essential for thiamine supply and may have a 
major impact on fetal growth and development (47).
intracellular Thiamine Metabolism
As previously outlined, inside the cytosolic compartment, free 
thiamine is first converted into the phosphorylated metabo-
lites ThMP, ThDP, and ThTP. Adenosine forms have also been 
identified, e.g., adenosine thiamine triphosphate (AThTP) 
and diphosphate (AThDP), however their function remains 
unclear (33).
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The synthesis of ThDP from free thiamine requires TPK, 
ATP, and magnesium, the deficit of which can limit clinical 
response to thiamine treatment (48, 49). ThDP is the biologi-
cally active form in the body (>80%) and serves as the most 
potent cofactor for thiamine-requiring enzymes (Figure  1B) 
(34). Most of the ThDP enters the mitochondrial matrix via 
the mitochondrial thiamine pyrophosphate transporter fam-
ily (M-ThPP-T) located in its inner membrane (Figure  1C3) 
(50). Of note, mutation in M-ThPP-T results in Amish lethal 
microcephaly–neuropathy (50).
Thiamine acts as a crucial cellular cofactor for several meta-
bolic enzymes studied in biochemical models (1, 2), namely the 
pyruvate dehydrogenase (PDH) multi-enzyme complex respon-
sible for the mitochondrial decarboxylation of pyruvate to acetyl-
CoA, the precursor to the Krebs cycle (Figure  1C3) (51), and 
alpha-ketoglutarate dehydrogenase (α-KGDH), responsible for 
the mitochondrial oxidative decarboxylation of α-ketoglutarate 
to succinyl-CoA (Figure 1C3) (36, 52). It also serves as a cofactor 
of cytosolic transketolase, a rate-limiting enzyme in the pentose 
monophosphate non-oxidative pathway leading to ribose then to 
nucleic acid synthesis (Figure 1C1) (53).
Upstream of the Krebs cycle, any functional defect in the 
PDH complex leads to anaerobic metabolism with an increase 
in cellular pyruvate and lactate (Figure  1B). This results in a 
build-up of these substrates in cerebrospinal fluid (CSF) and 
blood causing an elevation in the plasma anion gap (54–57). 
A recent report indicates that the consequent detrimental type 
B lactic acidosis is associated with a pseudo-hypoxia with no 
actual evidence of poor tissue perfusion or oxygenation. As a 
consequence, hypoxia-inducible transcription factor 1-alpha 
(HIF1-α) is increased and upregulates thiamine transporter 
gene expression [ThTr2 (SLCA19A3)] (Figures 1B,C2,C3) (58). 
Within the mitochondrial matrix, any earlier failed activities of 
PDH and α-KGDH can result in reduced ATP synthesis, which 
can induce an oxidative insult to the cell. Cascade reactions lead 
to the generation of damaging reactive oxygen species (ROS) and, 
ultimately, to apoptotic cell death (28, 31, 36, 59, 60). Additionally, 
in order for the Krebs cycle to function correctly it requires the 
operative integrity of PDH and α-KGDH enzymes that contribute 
to the synthesis of myelin and the neurotransmitter acetylcholine. 
Fully functional α-KGDH also preserves the physiological levels 
of other substrates (glutamate, gamma-amino butyric acid, and 
aspartate) (29, 36, 51).
Current research is investigating the role of thiamine in immune 
system regulation. There is evidence that its  non-coenzymatic 
function is involved in modulation of anti-inflammatory pro-
cesses and the expression of cytokine mediators (1, 3, 4).
CONDiTiONS AND RiSK FACTORS 
LeADiNG TO TD iN TROPiCAL 
PeDiATRiCS
Thiamine deficiency global prevalence is poorly documented. 
It principally affects precarious communities where children 
are most vulnerable and where dietary habits rely on refined 
processed cereals or tubers (e.g., rice, wheat, cassava), notably in 
Southeast Asia (5, 6, 10, 61–64), Africa (65–67) and, the Americas 
(68). These reports on TD prevalence vary from 13.4% of children 
admitted to hospital without signs of beriberi in Laos, 30% of 
Laotian children with uncomplicated malaria, 40% of severely 
malnourished children from Jamaica and Ghana, and up to 
100% of children with respiratory distress and tachycardia in one 
Indian study.
Thiamine deficiency can result from various mechanisms that 
are not mutually exclusive. The most frequent mechanisms are 
insufficiency of dietary thiamine (enteral–parenteral supply) and 
poor intestinal absorptive capacity during malnutrition, tropical 
enteropathy, or secondary to surgical resection of large portions 
of the gastrointestinal tract (11, 69–71). A relative inadequacy 
of thiamine content to caloric ratio (high carbohydrate diets) 
is also common. It is this thiamine–calorie imbalance that is 
responsible for TD in heavy drinkers of sweet drinks (72, 73) 
and contributes to the onset of TD when dextrose-based fluids 
are administered without thiamine supplementation in critically 
ill patients (74).
Poor thiamine intake may be due to losses from food secondary 
to pre-cooking and food processing (e.g., repetitive rice washing), 
a restrictive diet due to cultural habits (75) and ingestion of anti-
thiamine factors (tea leaves, betel nuts, and coffee) or thiaminases 
(e.g., fermented raw fish, mycotoxins, stored food, and larvae) 
that break down and, thus, inactivate thiamine (76, 77). Excessive 
loss of thiamine from the body, such as renal (loop diuretics, 
osmotic diabetic diuresis) or digestive losses (chronic diarrhea, 
hyperemesis), can also precipitate TD. At cellular level, two main 
mechanisms contribute to TD  –  impaired uptake or increased 
demand. Impaired cellular uptake of thiamine can be due to 
defects in thiamine transporters or specific enzymes (mutation, 
hypomagnesemia, drug-induced interaction), or reduced levels 
of ThDP. Increased cellular demand of thiamine occurs in hyper-
metabolic states during critical illness, e.g., severe infections, 
shock, burns, fever, hyperthyroidism.
Exposure to toxic substances, such as alcohol can also affect 
thiamine metabolism. When this occurs during pregnancy, the 
fetus may be indirectly affected, as observed in fetal alcohol syn-
drome (45–47, 78). Maternal TD associated with excessive alcohol 
consumption is usually secondary to inadequate thiamine intake 
or decreased intestinal absorption due to reduced expression of 
ThTr-1. In addition, impaired intracellular thiamine utilization 
affecting the TPK activity results in a low bioavailability of the 
active cellular ThDP due to ethanol and acetaldehyde exposure 
(2, 79–81).
In humanitarian fields, TD occurring in epidemic proportions 
has been described following abrupt food shortage caused by dis-
asters, famines, conflicts, or large population displacement (66, 
67, 76, 77, 82). In tropical pediatrics, the main cause of TD is poor 
thiamine intake, either by the child or by the mother for young 
infants. Associated co-morbidities are common and increase TD 
risk, for example, sepsis and shock during complicated severe 
acute malnutrition (SAM) are frequent and lead to an increase 
in mortality (83). Poor absorption, increased digestive losses and 
systemic inflammation can be aggravating cofactors in critically ill 
children. Additionally, pediatric intensive care practices in many 
resource-limited settings do not include thiamine as a component 
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of treatment, increasing TD risk even further. In emergency and 
tropical contexts, awareness of the clinical spectrum of TD and 
recognition of such cases could have a major impact on the 
management of sick children and, consequently, on under-five 
mortality (10, 56, 61, 67, 68, 82–84).
SYNDROMeS OF TD iN CHiLDReN
Classic Forms of Beriberi in infants
The earliest presentation of TD is in breastfeeding infants 
(1–3 months of age) with non-specific signs, including a “loud 
piercing cry” and colic (85). Refusal to breastfeed, constipation, 
vomiting, and agitation may also be present. Eventually edema, 
cyanosis, and congestive heart failure may appear. Shoshin 
beriberi, a fulminant form of congestive heart failure (cyano-
sis without edema) with type B lactic acidosis, has also been 
documented in infants (6, 54–56, 67, 71, 86). The administra-
tion of loop diuretics in such cases may unexpectedly worsen 
TD-related congestive cardiac failure due to increased renal 
thiamine clearance (87, 88), and TD should be suspected in any 
cardiogenic shock not responding to appropriate therapy (6). 
If undetected at this stage, death can occur within hours but 
prompt recognition and treatment with injectable thiamine can 
rapidly reverse the clinical picture and drastically improve the 
prognosis.
In this acute infantile form, TD results from a low thiamine 
content in breast milk among deficient, but mostly asymptomatic, 
mothers. Lactic acidosis may result in generalized symptoms, 
such as lethargy, irritability, anorexia, tachycardia, and tachypnea 
(64, 89). These clinical manifestations are probably secondary to 
dysfunction of mitochondrial energetics in the heart and smooth 
muscle (particularly the gastrointestinal tract), and an autonomic 
nervous system insult (6, 42, 43, 90). Due to the non-specific 
presentation, TD is often overlooked or misdiagnosed as typhoid 
fever, sepsis, malaria, pneumonia, or decompensated congenital 
cardiopathy in infants (5, 6, 71). TD may even be a cause of sud-
den infant death in this young age group (86, 90).
Later, at 4–7 months, the infant is more likely to present with 
an aphonic form. After increasing cough and dyspnea, the cry 
changes from hoarse to soundless (“aphonic cry”). Similar to the 
younger infant, without treatment this condition can evolve into 
severe acute congestive heart failure, edema, respiratory distress, 
and eventually death within a few days (86). The clinical appear-
ance at this stage is easily mistaken for severe croup, though TD 
is usually an afebrile condition. Laryngeal symptoms in TD are 
due to a Xth cranial nerve palsy caused by local nerve damage and 
voice changes may be worsened by laryngeal edema and general-
ized edema secondary to congestive heart failure, which are both 
observed in TD (6, 67, 89, 91).
Pediatric Neurological  
Manifestations of TD
Thiamine deficiency can present with a broad range of neurological 
signs in children, such as anorexia, irritability, agitation, muscle 
pain, diminished or abolished deep tendon reflexes, ataxia, paraly-
sis, and a progressively altered level of consciousness (67, 86, 92). 
Given the varied clinical presentations, any unexplained severe 
neurological signs or symptoms should raise the suspicion of TD. 
Nevertheless, three main neurological syndromes are described in 
children: pseudomeningitic beriberi in the first year of life, Enrick’s 
encephalopathy, and impaired cognitive development associated 
with mild chronic TD throughout infancy.
The onset of the pseudomeningitic form of infantile beriberi 
occurs at around 6–12  months of age. Clinical manifestations 
include muscular fasciculation, nystagmus, ophthalmoplegia, 
tense fontanel, seizures, and coma. If a lumbar puncture is per-
formed, CSF is found to be clear, with slightly high lactate and 
low  5-hydroxyindoleacetic acid (5-HIAA) levels (22, 86, 93, 94). 
This form of TD can be easily confused with encephalitis, men-
ingitis, cerebral-malaria, and vitamin A intoxication and should 
be included in the differential diagnosis of meningism in children 
(91, 95).
Nystagmus and ophthalmoplegia are attributed to lesions of 
the pons vestibular nuclei, and the nuclei of the third and the 
sixth cranial nerves of the periaqueductal region, respectively. 
The absence of significant destruction of neurons in these nuclei 
might explain the rapid reversal of the ocular and vestibular 
disturbances following thiamine administration. This suggests 
a continuous evolution from the “biochemical stage” to the 
irreversible organic lesions that are seen if left untreated (36, 52).
Although classically associated with alcoholism, Wernicke 
syndrome as a manifestation of TD is not limited to adults. Some 
children may develop a truncated Wernicke-like syndrome with-
out ataxia, while the classic triad of ophthalmoplegia or nystag-
mus, ataxia and altered consciousness, is more common in older 
children (69, 96–100). Typical lesions of TD should be sought 
in the cerebral targets of thiamine: the cerebellar–pons axis, the 
midbrain (periaqueductal gray matter and tectum), the mammil-
lary bodies, and the adjacent hypothalamic and thalamic regions 
(97, 98). Unlike in adults, pediatric brain MRI of Wernicke-like 
syndrome displays particular lesions in the frontal lobe and basal 
ganglia, notably the striatum and putamen. However, both adults 
and children affected by TD show the same symmetrical high-
intensity signal on T2 weighting in mammillary bodies and peri-
aqueductal and thalamic areas (97, 98, 100). Cerebral Spectrum 
MR displays a significant lactate doublet spike with changes in 
N-acetylaspartate/creatine and choline/creatine ratios, markers 
of neuronal damage and disruption to myelination, respectively 
(97, 100). Although rarely accessible in resource-limited settings, 
early detection of these lesions on neuroimaging could signifi-
cantly improve clinical outcome (97, 98, 100).
In addition to the acute neurological presentations described, 
more subtle neurological impairments due to chronic TD in 
infancy have been identified, particularly affecting cognitive 
development. Animal studies and clinical observations suggest 
that an undetected impairment in neuropsychological develop-
ment occurs during mild chronic thiamine depletion. In the long 
term, there is neurological damage causing cognitive and psycho-
motor troubles, alteration in the syntactic and lexical modalities of 
language acquisition, and seizures causing neurological sequelae 
(94, 101, 102). This highlights the importance of early diagnosis 
of TD during this critical period in infancy of accelerated learning 
and development of essential cognitive skills.
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Sepsis and Severe Acute Conditions 
Associated with, or exacerbated by 
Thiamine Deficiency
Severe acute conditions are often associated with functional or 
true TD in adults (103). Lima et al. (104) found that prevalence of 
TD on hospital admission was 28% in a Brazilian pediatric inten-
sive care unit,(104) while Khounnorath et  al. (5) documented 
biochemical TD in up to 13.4% of sick infants without evidence 
of overt beriberi (5). In tropical pediatrics, severe infections often 
occur on the background of malnutrition, with significant macro 
and micronutrient deficiencies already present. This may explain 
the much worse prognosis of septic shock in children with SAM, 
who potentially have an underlying TD exacerbated by sepsis 
(83). TD has been linked to an increase in mortality in severe 
acute conditions and shock, associated with both type A and B 
lactic acidosis (5, 57, 103). However, although Costa et al. (105) 
confirmed the high prevalence of TD in septic shock in intensive 
care patients (up to 71%), they were unable to show a consistent 
correlation with increased mortality (105).
Complex metabolic conditions may indirectly lead to TD or 
functional TD, for example, through increased digestive losses, 
poor thiamine intake during severe illnesses, and high turnover 
associated with hypermetabolic states, which leads to exhaustion 
of thiamine stores (74, 106). Critically ill children are often fast-
ing for the first 24 to 48 h of admission and parenteral nutrition 
in resource-poor settings is lacking. The use of dextrose-based 
maintenance fluids further potentiates TD risk due to the high 
consumption of thiamine in the glucose metabolic pathway, as 
previously outlined.
In sepsis, shock syndromes and severe acute conditions, the cur-
rent understanding is that hyperlactatemia (a prognostic indicator) 
is secondary to both type A acidosis, related to hypoxia, and type 
B acidosis, related caused by dysfunction of PDH in TD. Severe 
acute conditions lead to endogenous hypermetabolism with mito-
chondrial respiratory dysfunction. This causes an increase in both 
oxygen and thiamine consumption (as a PDH cofactor) because of 
a higher metabolic demand. The resulting functional TD induces 
a pseudohypoxic state, with the accumulation of pyruvate and lac-
tate, which in turn trigger the release of HIF1-α. HIF1-α, bound to 
its β subunit, regulates the expression of many genes, notably those 
involved in metabolic adaptability to hypoxia (gene expression 
for angiogenesis and erythropoietin synthesis) and innate system 
modulation (Figure 1C2) (58, 107). HIF1-α also favors anaerobic 
pathways via LDH gene expression and downregulation of the 
PDH complex (through PDK activation) in the mitochondria 
(Figure  1C3). In addition, HIF1-α is known to upregulate both 
Glut (glucose transporter) to increase uptake of glucose into the cell 
to meet the immediate demand for ATP via anaerobic pathways, 
and ThTr2 (thiamine transporter) synthesis at the transcriptional 
level in order to increase the intracellular thiamine pool pending 
the recovery of mitochondrial function (Figure 1C2).
This adaptive HIF1-α response may be beneficial in the face 
of rapid depletion of the thiamine pool caused by excessive 
utilization in severe acute conditions. In other words, the HIF1-α 
system creates the optimal cellular conditions to restart aerobic 
respiration once oxygenation and thiamine supply are restored. 
This is consistent with Donnino et  al.’s (108) recent findings 
that show the significant positive effect of administration of 
high-dose thiamine (400 mg) in a subgroup of adults with septic 
shock and TD (108). Moreover, the Zhu study (109) suggests 
that sepsis per  se might differentially block thiamine-carrier 
protein synthesis at the mRNA level and impair mitochondrial 
energetics in rat diaphragms. This would limit cellular thiamine 
entry, thus, another precipitating factor for functional TD (109). 
In these circumstances, much higher thiamine dosage than that 
recommended for beriberi would be required to counteract this 
phenomenon, as observed in Donnino’s trial (108).
The physician should suspect underlying TD in critically ill 
children with persistent lactic acidosis or increased plasma anion 
gap, as well as in any condition resulting in a hypermetabolic state 
such as shock, sepsis, large burns, poly-trauma, unexplained con-
gestive heart failure, congenital heart disease, diabetic ketoacido-
sis, and severe malaria (5, 54, 63, 71, 110–114).
induced-Thiamine Deficiency in  
Refeeding Syndrome
Thiamine deficiency or subclinical low vitamin B1 levels may 
be present in children with SAM, as reported in Jamaican and 
Ghanaian studies (~40–43%) (65, 68). This is most likely the 
result of a poor and monotonous diet, associated with malabsorp-
tion and thiamine loss caused by malnutrition-related diarrhea as 
well as a degree of intestinal epithelial atrophy (69, 84).
Refeeding syndrome is a potentially fatal complication of SAM 
management, especially when the introduction of food is too 
fast. Rapid initiation of nutritional rehabilitation also increases 
intracellular thiamine turnover which, on a background of 
pre-existing low whole body thiamine status, can precipitate the 
onset of true TD and may contribute to the mortality linked with 
refeeding syndrome (115–117).
Despite overlapping clinical pictures, refeeding syndrome and 
TD associated with refeeding do not share the same pathogenesis, 
with TD being a consequence of refeeding rather than a part of 
the syndrome (117). Refeeding syndrome itself is characterized by 
electrolyte imbalances caused by intracellular shift (e.g., hypophos-
phatemia, hypokalemia, hypomagnesemia), and leads to congestive 
heart failure with edema, neurological, and hematological compli-
cations. In induced TD, refeeding stimulates insulin production 
leading to protein synthesis and increased thiamine demand due 
to glucose utilization. Pre-existing low thiamine levels in SAM are 
further reduced by this increased cellular consumption of thiamine. 
As a result, mitochondrial enzyme complexes (PDH and alpha-
KGDH, dependent on their cofactor level) become dysfunctional 
and the glucose pathway is blocked at the level of pyruvate. The only 
alternative is for pyruvate to be channeled through the anaerobic 
pathway leading to type B lactic acidosis, a hallmark of acute TD.
Signs of refeeding syndrome and induced TD are often over-
looked or misinterpreted as sepsis, cardiac failure, pneumonia, 
or sudden death (116). In addition, thiamine assays are usually 
processed in highly specialized laboratory facilities, therefore, are 
rarely available in settings where SAM commonly occurs, making 
confirmed diagnosis rare in resource-limited settings (115). For 
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this reason, diagnosis of TD in this context relies on a high level 
of clinical awareness and suspicion.
Refeeding syndrome requires careful management, including 
adjustment of therapeutic milk volumes with consideration of 
calorie load, gradual correction of electrolyte imbalances and 
administration of a thiamine loading dose to prevent or correct 
refeeding-induced TD. Sydney Children’s Hospital Guidelines 
and Cape Town Pediatric Interest Group suggest 2  mg/kg of 
thiamine daily during the first week of SAM treatment to prevent 
refeeding syndrome and its consequences (118, 119). Although 
current international therapeutic feeding guidelines are designed 
to provide optimal SAM management and avoid complications, 
high-dose thiamine at initiation of treatment is not the current 
practice in humanitarian settings (84). Since we know that a 
number of children with complicated SAM have borderline 
thiamine stores, even very cautious introduction of feeds may 
trigger refeeding syndrome and induced TD without the addition 
thiamine supplementation.
Acute Clinical Syndromes  
Associated with Thiaminases
Traditional diets, including fermented fish (containing 
thiaminase) and betel nut (containing thiamine antagonists) 
can precipitate symptoms of TD in a nutritional context of high 
carbohydrate monotonous diet, such as polished rice (66, 77).
However, the most striking clinical manifestation of TD 
associated with thiaminases is African Seasonal Ataxia. Small 
case series’ or large outbreaks (described in western Nigeria), 
related to the consumption of thiaminase-containing Anaphe 
venata larva, are described during the rainy season (91, 120). 
Patients develop nausea, vomiting, and dizziness within hours of 
thiaminase ingestion. Subsequently, fulminant neurological signs 
develop with nystagmus, tremor, cerebellar ataxia, dysarthria, 
confusion, and eventually coma. If the diagnosis is suspected 
early, treatment with thiamine bolus rapidly relieves symptoms 
and reverses coma within 72 h, suggesting a massive depletion of 
whole body thiamine caused by thiaminase.
A recent report of infant botulism was found to be associated 
with clostridium production of thiaminase I, inducing TD. It was 
speculated that the paralysis of this patient due to clostridium 
neurotoxins was in fact aggravated by TD. Indeed, the adminis-
tration of thiamine resulted in faster improvement and a shorter 
clinical course (121).
DiAGNOSiS AND TReATMeNT
Thiamine deficiency can be investigated using plasma, erythro-
cytes, whole blood ThPP levels (22, 33), and urinary excretion 
of thiamine before and after exogenous thiamine administration 
(7). However, serum or whole blood thiamine has poor sensitivity 
and specificity in severe acute conditions as it decreases during 
systemic inflammation, and represents only a small part of the 
whole body thiamine pool. Erythrocyte transketolase activity 
more accurately evaluates the thiamine status of the body and 
is, therefore, used as standard (9). MR imaging showing specific 
lesions can also be very helpful in early detection of neurologic 
features of TD (97, 100). However, none of these investigations 
allow immediate diagnosis of TD in life-threatening conditions 
and they are rarely available in resource-limited settings.
Consequently, the diagnosis of TD in such contexts is a real 
challenge, especially considering its wide and non-specific clinical 
spectrum and potentially fatal prognosis. A high level of clinical 
suspicion should be demonstrated in the following situations (5, 
6, 54): suspicion of infantile beriberi; unexplained neurological 
signs, encephalitis, and cardiac failure; early clinical deterioration 
after initiation of feeds in malnutrition; sepsis (including in SAM); 
severe burns; major trauma; hypoxia; and unresponsive lactic 
acidosis. Rapid point of care lactate testing can be used to confirm 
persistent lactic acidosis despite correction of shock, and could 
help to raise the suspicion of TD (54, 57, 58). However, in the 
absence of specific diagnostic tests, the only way to diagnose TD 
is to carry out a therapeutic thiamine challenge. Considering its 
safety profile and wide dosage range, in such cases, thiamine can be 
administered by slow intravenous injection over 30 min. In severe 
acute conditions caused by TD, rapid clinical improvement will 
be seen (within hours or days) following thiamine administration.
Evidence-based pediatric thiamine dosage recommendations 
for severe acute illness are lacking. Doses found in this literature 
review vary from 50 to 1500 mg depending on the clinical condi-
tion (7, 9, 86, 91, 122), with neurological presentations potentially 
requiring higher doses and having a longer recovery time (a few 
days). A recent study showed that thiamine-deficient adults with 
septic shock in ICU had a significantly lower mortality if they 
received thiamine 200  mg twice daily for a week compared to 
placebo (108). Rao and Chandak (6) used 150 mg IV thiamine 
to treat breast-fed infants under 6 months of age presenting with 
cardiac failure and/or tachypnea (6), while Qureshi et al. success-
fully treated lactic acidosis in younger infants (aged 32 days to 
4 months) with 100 mg of thiamine daily (89). In both studies, 
thiamine was well tolerated.
Given this evidence, early thiamine injection in children with 
severe acute conditions should be considered as a complementary 
resuscitation tool, especially when there is co-existing malnutrition 
or where dextrose-based fluid is used to resuscitate (6, 90, 99). 
Switching to the enteral route should be considered as soon as pos-
sible after the initial thiamine bolus (54, 123, 124). In addition to 
optimal dosage, practical aspects of drug dilution and calculation 
must be taken into account in resource-poor settings where staff are 
not always highly qualified. For example, 100 mg is an easy dose to 
prepare and administer for preparations of 100 mg/ml of thiamine.
According to the literature, prevention of TD during the early 
refeeding phase in complicated SAM initially requires 10–30 mg 
of thiamine daily followed by 5–10 mg daily for a month (74, 119, 
125). This is not standard practice in humanitarian programs and 
would provide 10–20 times more than currently recommended in 
therapeutic protocols, as shown in Table 1 (84, 119). One sachet 
of ready-to-use therapeutic food (RUTF) or 600 ml of therapeutic 
milk [either of F-75 (75 kcal/100 ml) or F-100 (100 kcal/100 ml)] 
contain an average of 0.5 mg of thiamine (84); thus, the average 
daily intake represents 1–2 mg at most. This is even more signifi-
cant in infants under 6 months of age with SAM who are at greater 
risk of developing TD. These babies receive neither RUTF, F-75 
TABLe 1 | Thiamine content of therapeutic milk and estimated thiamine 




Approximate amount of F-75 
(milliliter and equivalent of thiamine 
content) given in 8 meals/day in 
acute stabilization phase according 
to refeeding protocols [wHO (84)]
South African and 
Australian guidelines for 
prevention of refeeding 
syndrome (2 mg/kg of 
thiamine) (118, 119)
5 8 × 85 ml/day (~0.5 mg of thiamine) 10 mg of thiamine 
7 8 × 120 ml/day (~0.8 mg of thiamine) 14 mg of thiamine
10 8 × 170 ml/day (~1.1 mg of thiamine) 20 mg of thiamine
15 8 × 250 ml/day (~1.7 mg of thiamine) 30 mg of thiamine 
SAM, severe acute malnutrition; F-75 is the therapeutic milk used during early refeeding 
(75 kcal/100 ml). As an example, a 7 kg child with complicated SAM would be given 
eight meals of 120 ml of F-75 on admission. Applying above guidelines (third column) 
would represent approximately 17 times more thiamine.
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nor F-100 but only breast milk or specially diluted F-100, and 
breastfeeding mothers are rarely supplemented. Infants under 
6  months should, therefore, be supplemented with thiamine 
(2 mg/kg) in order to minimize the risk of precipitating TD.
Adding weight to the benefits of thiamine supplementation, 
Luxemburger et  al. (82) showed thiamine distribution in a 
population with high prevalence of TD (Karen refugees’ camps) 
to be clinically significant. Pregnant women with overt signs of 
TD received 100  mg of thiamine daily until delivery, followed 
by 10 mg weekly until 9 months after birth for both mother and 
infant. Highly relevant results showed overall reductions in infant 
mortality rate from 183 to 78 per 1000 live births, case fatality of 
infantile beriberi from 100 to 7%, postnatal deaths by 79% (CI95% 
65–87%), and mortality attributable to beriberi from 73 to 5 per 
1000 (P < 0.0001) (82).
In summary, based on current evidence, we propose that a 
therapeutic challenge of 100 mg of thiamine should be given in 
acute severe illness and in clinically evident TD. For prevention of 
TD in high-risk situations, such as nutritional and humanitarian 
crises, refugee, and displaced populations, mass thiamine weekly 
distribution of 10–30  mg could be considered. The thiamine 
content of therapeutic foods should also be re-evaluated to mini-
mize TD during the initial phase of refeeding. This must include 
RUTF, as most SAM patients are treated as out-patients. Finally, 
pregnant women with a suspicion of TD should receive thiamine 
treatment during pregnancy, and both mother and baby should 
continue supplementation while breastfeeding.
CONCLUSiON
This review highlights new perspectives on pathophysiological 
and clinical correlations in pediatric TD. Thiamine is an intra-
cellular micronutrient with ubiquitous body distribution and 
plays a fundamental role in mitochondrial energetics within its 
key target organs. The article outlines the intracellular thiamine 
transporter traffic and explains the association of TD with type B 
lactic acidosis and dysfunction of the Krebs cycle, indicating that 
TD should be considered as a form of acquired functional mito-
chondrial disease in pediatrics. This review also sheds light on the 
important role of thiamine in refeeding syndrome and in critical 
illness. In such circumstances, there is evidence of a mismatch 
between the increased endogenous metabolic requirements and 
cellular thiamine availability.
Thiamine deficiency has a large clinical spectrum, and as such 
it is frequently misdiagnosed, sometimes with fatal consequences 
or permanent neurological sequelae. Even classic beriberi is still 
often unrecognized, and increased clinical awareness is essential. 
Early treatment with thiamine has the potential to rapidly reverse 
clinical signs and minimize sequelae, before the onset of fixed 
lesions. The lack of diagnostic capacity in resource-poor settings 
justifies the use of a therapeutic thiamine challenge in cases with 
high clinical suspicion. It is an effective, inexpensive, and easy to 
administer medication.
Many risk factors for TD coexist in tropical pediatrics, making 
it a highly relevant public health issue. This review provides an 
opportunity to raise awareness of TD prevalence in malnour-
ished and critically ill children, and to consider early systematic 
thiamine treatment and clarification of the role of thiamine in 
the algorithms of metabolic resuscitation. Finally, it calls into 
question the current thiamine content of RUTF and milk in 
therapeutic feeding programs, and provides arguments for added 
thiamine supplementation in therapeutic foods for malnutrition.
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